Richard Steinhart - May 14, 2023 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Signature
/s/ Richard Steinhart
Stock symbol
BTAI
Transactions as of
May 14, 2023
Transactions value $
-$135,864
Form type
4
Date filed
5/16/2023, 08:32 PM
Previous filing
May 5, 2023
Next filing
Jun 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTAI Common Stock Options Exercise +5K +333.33% 6.5K May 14, 2023 Direct F1
transaction BTAI Common Stock Sale -$136K -5K -76.92% $27.17 1.5K May 15, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Restricted Stock Units Options Exercise $0 -5K -100% $0.00* 0 May 14, 2023 Common Stock 5K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 23, 2022.
F3 The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $26.84 to $27.63. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F4 On May 14, 2022, the Reporting Person was granted 5,000 RSUs that vested and settled on May 14, 2023.